<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652818</url>
  </required_header>
  <id_info>
    <org_study_id>CP-NVK009-0001</org_study_id>
    <nct_id>NCT03652818</nct_id>
  </id_info>
  <brief_title>Dental Pain Study of Analgesics in Patients Undergoing Molar Removal</brief_title>
  <acronym>NVK009-0001</acronym>
  <official_title>Randomized, Double-blind, Parallel Group, Single-center, Placebo-controlled Study to Evaluate Efficacy and Safety of Analgesic Combo in Prevention and Treatment of Post-surgical Dental Pain in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nevakar, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nevakar, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Accessing the efficacy and safety of pregabalin when used alone and in combo with
           acetaminophen in a dental pain model.

        -  To test whether pre-operative dose of pregabalin increases the time to significant
           post-operative pain (NRS ≥ 5), and hence time to first analgesia consumed
           post-operatively.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a 5 arm randomized, double-blind, parallel group, single-center, placebo-controlled
      study to evaluate the efficacy and safety of pregabalin-acetaminophen combination in the
      prevention and treatment of post-surgical dental pain in healthy patients.

      Subjects in every treatment arm will receive a dose 60 min prior to surgery. It is not
      required to receive a post-operative dose if patient does not feel pain at a scale of NRS≥ 5.
      Dose 2 will be given post-surgically when patients report at least moderate pain on the
      categorical scale and a score of ≥5 on 0-10 PI-NRS. Subsequent to dose 2, patients can
      request rescue analgesic at any time.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2018</start_date>
  <completion_date type="Actual">September 20, 2018</completion_date>
  <primary_completion_date type="Actual">September 20, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>The sponsor, patients, investigators and study staff involved in the protocol procedures or those involved in data collection, data entry, data analysis will be blinded.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Pain Intensity Measure</measure>
    <time_frame>24 Hours</time_frame>
    <description>Beginning post-surgery (at initiation of Dose 2), Pain Intensity will be self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = pain as bad as can be).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pain Relief Measure</measure>
    <time_frame>24 Hours</time_frame>
    <description>Beginning post-surgery (at initiation of Dose 2), Pain Relief will be self-reported over 24 hours, using a pain rating of 0-10 on the Numerical Rating Scale (NRS), with score between 0-10 (0= no pain; 10 = pain as bad as can be).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Global Evaluation Measure</measure>
    <time_frame>24 Hours</time_frame>
    <description>Patient global evaluation will be self-reported over 24 hours, using a 0-4 categorical rating scale of: (0) poor, (1) fair, (2) good, (3) very good, and (4) excellent.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First Perceptible Relief (FPR) Measure</measure>
    <time_frame>24 Hours</time_frame>
    <description>Beginning post-surgery (at initiation of Dose 2), patients will be given a stopwatch and asked to press the stopwatch if and when they feel first perceptible relief; a record of the time will be noted in the patient record.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Meaningful Perceptible Relief (MPR) Measure</measure>
    <time_frame>24 Hours</time_frame>
    <description>Beginning post-surgery (at initiation of Dose 2), patients will be given a second stopwatch and asked to press the stopwatch if and when they feel any meaningful perceptible relief; a record of the time will be noted in the patient record.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">115</enrollment>
  <condition>Dental Pain</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-op Placebo 1;
Post-op Placebo 1;
Post-op Placebo 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-op Placebo 1;
Post-op Placebo 2;
Post-op acetaminophen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-op Placebo 1;
Post-op pregabalin;
Post-op Placebo 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-op Placebo 1;
Post-op pregabalin
Post-op acetaminophen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-op pregabalin;
Post-op Placebo 1;
Post-op acetaminophen.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-Op pregabalin</intervention_name>
    <description>Pre-op pregabalin will be administered 60 min prior to surgery.</description>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pre-Op Placebo 1</intervention_name>
    <description>Placebo 1 will be administered 60 min prior to surgery.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <other_name>pre-op placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-Op pregabalin</intervention_name>
    <description>Post-op pregabalin will be administered Post-operatively.</description>
    <arm_group_label>Group C</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-Op Placebo 1</intervention_name>
    <description>Placebo 1 will be administered post-operatively.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-Op Placebo 2</intervention_name>
    <description>Placebo 2 will be administered post-operatively.</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Post-Op acetaminophen</intervention_name>
    <description>Acetaminophen will be administered Post-operatively.</description>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_label>Group D</arm_group_label>
    <arm_group_label>Group E</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are scheduled to undergo the surgical removal of up to 4 third molars of
             which at least 2 have to be mandibular molars with a difficulty rating of 4 or 5.

          -  Patient must have a negative urine drug screen for drugs of abuse (including tobacco)
             at screening and at the day of surgery.

          -  No alcohol for a minimum of 1 day prior to the surgery.

        Exclusion Criteria:

          -  Patients should not be experiencing oral infections or symptoms of concomitant illness
             at the time of a scheduled surgery.

          -  Patients with a history of any type of malignancy within the past 5 years other than
             minor skin related cancers.

          -  Patients who currently have or have had a history of uncontrolled hypertension.

          -  Patients with a known allergy or hypersensitivity to any local anesthetic drug,
             NSAIDs, gabapentin or pregabalin;.

          -  Patients with conditions that affect the absorption, metabolism, or passage of drugs
             out of the body (e.g., sprue, celiac disease, crohn's disease, etc.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kenneth Somberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nevakar, LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jean Brown Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>July 18, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 20, 2019</last_update_submitted>
  <last_update_submitted_qc>August 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Toothache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Pregabalin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

